ES555542A0 - Procedimiento para preparar derivados de imidazo(1,5-a)piridina - Google Patents

Procedimiento para preparar derivados de imidazo(1,5-a)piridina

Info

Publication number
ES555542A0
ES555542A0 ES555542A ES555542A ES555542A0 ES 555542 A0 ES555542 A0 ES 555542A0 ES 555542 A ES555542 A ES 555542A ES 555542 A ES555542 A ES 555542A ES 555542 A0 ES555542 A0 ES 555542A0
Authority
ES
Spain
Prior art keywords
alkyl
piridina
procedure
formula
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES555542A
Other languages
English (en)
Other versions
ES8802049A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES555542A0 publication Critical patent/ES555542A0/es
Publication of ES8802049A1 publication Critical patent/ES8802049A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES555542A 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina Expired ES8802049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/622,421 US4617307A (en) 1984-06-20 1984-06-20 Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors

Publications (2)

Publication Number Publication Date
ES555542A0 true ES555542A0 (es) 1988-03-16
ES8802049A1 ES8802049A1 (es) 1988-03-16

Family

ID=24494112

Family Applications (6)

Application Number Title Priority Date Filing Date
ES544344A Expired ES8702406A1 (es) 1984-06-20 1985-06-19 Procedimiento para preparar derivados de imidazo (1,5-a) pi-ridina
ES555539A Expired ES8802155A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina
ES555540A Expired ES8801262A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidiazo (5,5-a) piridina.
ES555541A Expired ES8800681A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina
ES555542A Expired ES8802049A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina
ES555538A Expired ES8802048A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES544344A Expired ES8702406A1 (es) 1984-06-20 1985-06-19 Procedimiento para preparar derivados de imidazo (1,5-a) pi-ridina
ES555539A Expired ES8802155A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina
ES555540A Expired ES8801262A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidiazo (5,5-a) piridina.
ES555541A Expired ES8800681A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES555538A Expired ES8802048A1 (es) 1984-06-20 1986-05-30 Procedimiento para preparar derivados de imidazo(1,5-a)piridina

Country Status (31)

Country Link
US (1) US4617307A (es)
EP (1) EP0165904B1 (es)
JP (1) JPS6112688A (es)
KR (1) KR900008566B1 (es)
AT (1) ATE62415T1 (es)
AU (1) AU589565B2 (es)
BG (7) BG60262B1 (es)
CA (1) CA1276633C (es)
CS (1) CS268672B2 (es)
CY (1) CY1750A (es)
DD (1) DD237510A5 (es)
DE (1) DE3582452D1 (es)
DK (1) DK170302B1 (es)
DZ (1) DZ799A1 (es)
ES (6) ES8702406A1 (es)
FI (1) FI80694C (es)
GR (1) GR851487B (es)
HK (1) HK23494A (es)
HU (1) HU202529B (es)
IE (1) IE58070B1 (es)
IL (1) IL75546A (es)
MA (1) MA20459A1 (es)
MX (1) MX9203369A (es)
NO (1) NO162467C (es)
NZ (1) NZ212483A (es)
PH (1) PH23390A (es)
PL (6) PL145348B1 (es)
PT (1) PT80661B (es)
RO (1) RO92583A (es)
SU (6) SU1433413A3 (es)
ZA (1) ZA854615B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5171858A (en) * 1985-06-05 1992-12-15 Schering A.G. Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4797411A (en) * 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
US5066656A (en) * 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
EP0514015A1 (en) * 1991-04-19 1992-11-19 Merck & Co. Inc. Control of sex differentiation in fish
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
JPH05176659A (ja) * 1991-04-26 1993-07-20 Merck & Co Inc 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5587392A (en) * 1994-05-27 1996-12-24 Mochida Pharmaceutical Co., Ltd. Azolyl methyl phenyl derivatives having aromatase inhibitory activity
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2003250190A1 (en) * 2002-07-30 2004-02-23 Novartis Ag Combination of an aromatase inhibitor with a bisphosphonate
CA2494636A1 (en) * 2002-08-07 2004-02-19 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
CN100447142C (zh) * 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US20080161321A1 (en) 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
US8680079B2 (en) * 2004-05-28 2014-03-25 Novartis Ag Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors
JP2008500998A (ja) * 2004-05-28 2008-01-17 シュペーデル・エクスペリメンタ・アーゲー 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20100240641A1 (en) * 2006-05-26 2010-09-23 Julien Papillon Aldosterone Synthase and/or 11B-hydroxylase Inhibitors
PL2049517T3 (pl) 2006-07-20 2014-06-30 Novartis Ag Pochodne amino-piperydyny jako inhibitory CETP
KR20090055595A (ko) * 2006-08-25 2009-06-02 노파르티스 아게 알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
WO2009071509A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR086665A1 (es) 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
AP2014007762A0 (en) * 2012-01-17 2014-07-31 Novartis Ag New forms and salts of a dihydropyrrolo[1,2C]imidazolyl aldosterone synthase or aromatase inhibitor
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
UY35671A (es) 2013-07-25 2015-02-27 Novartis Ag Bioconjugados de polipéptidos de apelina sintética
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
SI3250555T1 (sl) * 2015-01-29 2021-08-31 Recordati Ag Postopek za proizvodnjo kondenziranih imidazolo derivatov
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JP2016074729A (ja) * 2015-12-31 2016-05-12 国立大学法人 千葉大学 イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018078049A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
BR112020022173A2 (pt) 2018-05-03 2021-02-02 Damian Pharma Ag r-fadrozol para uso no tratamento de aldostonerismo
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (es) * 1971-03-15 1976-07-24
FR2449689A1 (fr) * 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
CA1250844A (en) * 1981-06-22 1989-03-07 Neville Ford Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US4409226A (en) * 1981-10-05 1983-10-11 Schering Corporation Imidazo[1,5-a]pyridines
US4361567A (en) * 1981-10-05 1982-11-30 Schering Corporation Treatment of peptic ulcer disease
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors

Also Published As

Publication number Publication date
HUT37936A (en) 1986-03-28
FI852399A0 (fi) 1985-06-17
FI80694C (fi) 1990-07-10
ES555540A0 (es) 1987-12-16
EP0165904A3 (en) 1987-09-09
PL145104B1 (en) 1988-08-31
MX9203369A (es) 1992-09-01
SU1482530A3 (ru) 1989-05-23
BG60262B2 (en) 1994-03-31
KR900008566B1 (ko) 1990-11-24
CA1276633C (en) 1990-11-20
PT80661B (en) 1987-05-04
SU1436879A3 (ru) 1988-11-07
CY1750A (en) 1994-06-03
ES544344A0 (es) 1987-01-01
EP0165904A2 (de) 1985-12-27
NO162467B (no) 1989-09-25
SU1433413A3 (ru) 1988-10-23
BG60306B2 (bg) 1994-07-25
ES8802049A1 (es) 1988-03-16
DK170302B1 (da) 1995-07-31
PH23390A (en) 1989-07-26
DE3582452D1 (de) 1991-05-16
IL75546A (en) 1990-01-18
BG60305B2 (bg) 1994-07-25
IL75546A0 (en) 1985-10-31
SU1436880A3 (ru) 1988-11-07
DK277685A (da) 1985-12-21
IE851520L (en) 1985-12-20
SU1443802A3 (ru) 1988-12-07
MA20459A1 (fr) 1985-12-31
ES8800681A1 (es) 1987-11-16
ES555539A0 (es) 1988-04-01
BG60262B1 (bg) 1994-03-31
HU202529B (en) 1991-03-28
DD237510A5 (de) 1986-07-16
DZ799A1 (fr) 2004-09-13
ES555538A0 (es) 1988-03-16
FI852399L (fi) 1985-12-21
GR851487B (es) 1985-11-25
HK23494A (en) 1994-03-25
BG60352B2 (bg) 1994-11-30
ES8802048A1 (es) 1988-03-16
PL145105B1 (en) 1988-08-31
PL145087B1 (en) 1988-08-31
NZ212483A (en) 1988-10-28
EP0165904B1 (de) 1991-04-10
CS268672B2 (en) 1990-04-11
PL145103B1 (en) 1988-08-31
FI80694B (fi) 1990-03-30
ATE62415T1 (de) 1991-04-15
BG60307B2 (en) 1994-07-25
CS444985A2 (en) 1989-07-12
KR860000299A (ko) 1986-01-27
JPH047746B2 (es) 1992-02-12
ES555541A0 (es) 1987-11-16
ES8702406A1 (es) 1987-01-01
SU1436878A3 (ru) 1988-11-07
US4617307A (en) 1986-10-14
PL145814B1 (en) 1988-11-30
AU4385785A (en) 1986-01-02
ZA854615B (en) 1986-02-26
AU589565B2 (en) 1989-10-19
IE58070B1 (en) 1993-06-30
BG60353B2 (bg) 1994-11-30
JPS6112688A (ja) 1986-01-21
PT80661A (en) 1985-07-01
NO162467C (no) 1990-01-10
ES8802155A1 (es) 1988-04-01
RO92583A (ro) 1987-11-30
PL145348B1 (en) 1988-09-30
PL254099A1 (en) 1986-09-09
BG60402B2 (bg) 1995-02-28
ES8801262A1 (es) 1987-12-16
NO852474L (no) 1985-12-23
DK277685D0 (da) 1985-06-19

Similar Documents

Publication Publication Date Title
ES555538A0 (es) Procedimiento para preparar derivados de imidazo(1,5-a)piridina
DK158087D0 (da) Hidtil ukendte benzothiazinderivater og sammensaetning indeholdende samme
IT1201963B (it) Derivati delle rifamicine e procedimento per la loro preparazione
ES504259A0 (es) Procedimiento para la obtencion de nuevos derivados de la tiazolo (3,2-a) pirimidina
ES519530A0 (es) Procedimiento para la preparacion de tienobenzodiazepinonas sustituidas.
SE8303719L (sv) Eburnan-oximderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer

Legal Events

Date Code Title Description
PC1A Transfer granted
FD2A Announcement of lapse in spain

Effective date: 20151230